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Abstract
Background: Genetic screens using CRISPR/Cas9 are a powerful method for the functional analysis of genomes.
Results: Here we describe CRISPR library designer (CLD), an integrated bioinformatics application for the design of
custom single guide RNA (sgRNA) libraries for all organisms with annotated genomes. CLD is suitable for the design
of libraries using modified CRISPR enzymes and targeting non-coding regions. To demonstrate its utility, we
perform a pooled screen for modulators of the TNF-related apoptosis inducing ligand (TRAIL) pathway using a
custom library of 12,471 sgRNAs.
Conclusion: CLD predicts a high fraction of functional sgRNAs and is publicly available at https://github.com/
boutroslab/cld.
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Background
The clustered regularly interspaced short palindromic
repeats (CRISPR)-associated RNA-guided endonuclease
Cas9 can be utilized in eukaryotic cells to introduce
double-strand breaks at specific genomic sequences [1,
2]. There, the error-prone repair of double-strand breaks
by non-homologous end joining results in nucleotide
deletions and insertions, which can lead to gene inacti-
vation. Further modifications of Cas9 have been devel-
oped, allowing for screening with activation (CRISPRa)
or repression (CRISPRi) of target gene expression [3, 4].
Specificity of Cas9 knockout can be further enhanced by
applying Cas9-nickase [5] or high fidelity Cas9 variants
[6]. CRISPR/Cas9 technology works efficiently in many
species [7–9] and the simplicity of this method allows
screening in both cell culture [10–15] and whole organ-
isms [8, 16]. In addition to the currently available human
and murine genome-scale CRISPR libraries, there is a
growing need for single guide RNA (sgRNA) libraries for
custom gene sets, other organisms, and CRISPR type II
endonucleases using alternative protospacer adjacent
motif (PAM) sites such as Cpf1 [17]. While several web
services for the gene-by-gene design of sgRNAs have
been developed [18–22], integrated and flexible bioinfor-
matics workflows for the design of custom sgRNA librar-
ies are currently lacking.
Here, we present the CRISPR library designer (CLD)
software, which implements an end-to-end design of
custom sgRNA libraries targeting the genomes of many
different species. We used this method to design a cus-
tom sgRNA library and performed a pooled screen to
identify all known essential components of the TNF-
related apoptosis-inducing ligand (TRAIL) pathway.
Implementation
The CLD software package implements an end-to-end
design of custom sgRNA libraries targeting the genomes
of many different species. CLD automates all tasks for
the generation of sgRNA libraries. It can design libraries
of variable size ranging from a few hundred genes to
genome-scale for all annotated genomes available from
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ENSEMBL [23]. CLD implements the following steps: (i)
it downloads and reformats ENSEMBL databases, (ii)
predicts and filters sgRNA target sites for a provided list of
genes, and (iii) reports the results in a ‘ready-to-order’
library file containing nucleotide sequences for on-chip syn-
thesis and subsequent cloning into target vectors. Figure 1
shows the schematic workflow of CLD. CLD requires three
input files: the genome sequence, a parameter file, and a
gene list. To ensure flexibility, genome sequence files can
be downloaded either from ENSEMBL or as pre-calculated
files from our website (http://www.dkfz.de/signaling/crispr-
downloads/). In addition, the user supplies a parameter file
to adapt design options, i.e., target site length, target region,
or number of tolerable off-targets (Additional file 1: Table
S1). These parameters enable the construction of custom li-
braries optimized for a broad spectrum of experimental ap-
plications. The third input file is a list of gene identifiers
or genomic coordinates of regions to be targeted by
sgRNAs (Additional file 2: Table S2). All input informa-
tion can also be supplied via a user-friendly, graphical user
interface (GUI). Target sites are identified using an algo-
rithm which scans each gene for all possible sgRNA sites
[24, 25]. A pattern-matching algorithm first indexes all
PAM sequences by nucleotide positions and then searches
this index to find matches. All potential sgRNAs (e.g., over
3000 for the human MAPK1 gene) are then further filtered
by user-defined criteria. In order to identify sgRNAs target-
ing specific, user-defined gene regions, CLD uses an inter-
val tree containing all annotations of the genome. The user
defines filtering parameters (e.g., coding regions, target
length, exon targeting, start and stop codon targeting),
which enable the design of libraries against protein-coding
and non-coding genes or transcription start sites for CRIS-
PRi and CRISPRa applications [4, 26] (see also Additional
file 3: Figure S1). Target sequences of sgRNAs, which pass
all filter criteria, are mapped to the genome of interest in
order to identify up to 30 potential off-targets. Selection cri-
teria for on- and off-targets can be custom defined includ-
ing tolerance of mismatches at different nucleotide
positions. On-target efficiency and frequency of off-target
sites are then assessed by different scoring algorithms. First,
potential off-target sites are identified using user defined
alignment algorithms (bowtie, bowtie2, blastn-short) [27–
29] and summarized in the specificity score. Then, the an-
notation score evaluates the target position of sgRNAs
within the respective gene model. Finally, the nucleotide
composition surrounding the target site is evaluated via the
algorithms published by Doench et al. [30] and Xu et al.
[31]. In addition, the user may supply a custom scoring al-
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Fig. 1 CRISPR library designer workflow. CLD is a command line tool, tailored for fast end-to-end design of sgRNA libraries. Its back-end
steps are performed by the depicted algorithm: the genome data of the target organism, a gene list of interest, and a parameter file are
needed as input files. Each gene sequence is then scanned for the presence of protospacer adjacent motifs (PAM). Valid target sites are evaluated for their
annotation, sequence, and off-target characteristics and passed to the library formatting steps. There, target sites are tested for specific restriction sites and
then flanked by cloning adapters. A user-defined minimum of best-annotated sgRNAs is selected for each gene. Genes with sgRNA coverage below the
defined minimum are discarded. In the end, output files are generated, including a FASTA file containing ready-to-order oligonucleotide sequences
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(for details, see Methods, sgRNA scoring). Each sgRNA is
ranked by specificity and annotation score. Additional rank-
ing by Doench or Xu score can be selected. Next, target site
sequences are processed to generate sgRNAs suitable for
subsequent cloning steps, including addition of adapters
and exclusion of specific restriction sites. Genes with cover-
age below a user-given threshold can be excluded. Finally,
all data are reformatted into standardized file formats (GFF,
FASTA, SAM; Additional file 4: Table S3). CLD can be run
efficiently on desktop workstations (two to eight cores,
8 GB RAM) for smaller genomes or medium size gene lists.
High-complexity genome-wide libraries have been calcu-
lated in <1 h on a 96 CPU server cluster.
Results and discussion
A pooled CRISPR/Cas9 screen for validation of CLD
To test the functionality of CLD, we designed a custom,
ultra-complex library and tested it in a pooled screen in
human cancer cells (raw data are provided in Additional
file 5: Table S4, Additional file 6: Table S5, Additional
file 7: Table S6, Additional file 8: Table S7). We chose to
screen for modulators of TRAIL-induced apoptosis, as
depletion of TRAIL pathway components results in dis-
tinct pro- or anti-apoptotic phenotypes [32]. Our custom
library was composed of 12471 sgRNAs targeting 408 genes
and including 200 non-targeting, randomly designed con-
trol sgRNAs (Additional file 3: Figure S3, Additional file 9:
Table S8). We included positive (e.g., CASP8, BAX, FADD)
and negative regulators (e.g., BCL2L1) of the TRAIL path-
way, together with a large number of human protein ki-
nases (Additional file 2: Table S2). Each gene was targeted
by 30 different sgRNAs. The genes BAX, CASP8, and
FADD served as positive controls and were targeted with
approximately 100 sgRNAs. SW480 cells stably expressing
Cas9 were transduced with the lentiviral sgRNA library.
The pool of mutant cells was treated with either recombin-
ant TRAIL or phosphate buffered saline (PBS) (Fig. 2a).
The results of the screen showed that sgRNAs of specific
genes were enriched or depleted upon TRAIL treatment,
including known positive (e.g., CASP8, BAX, FADD) and
negative regulators (e.g., XIAP, BCL2L1) (Fig. 2e, f;
Additional file 3: Figure S2). Essential components of the
pathway, such as CASP8 or FADD, showed an average
enrichment of approximately fourfold compared with non-
targeting controls (p < 10-3, Wilcoxon rank sum test)
(Fig. 2d). The receptors for TRAIL ligands (TNFRSF10A/
DR4, TNFRSF10B/DR5), which are partially redundant
[33], showed a weaker enrichment (Additional file 3: Figure
S2a–c). sgRNAs against known negative regulators of the
pathway are depleted with an average fold change of ~2
Fig. 2 A pooled screen for functional validation of CLD. a The screening strategy in SW480 cells. In brief, a pool of mutant SW480 cells harboring
12,471 sgRNA designs against 408 genes was generated by lentiviral infection and antibiotic selection. Fourteen million cells per condition were
then treated with PBS (control) or recombinant TRAIL (treatment) for a total of 12 days. Subsequently, the genomic DNA of the samples was extracted
and sgRNA composition analyzed by next-generation sequencing (NGS). b Comparison of sgRNA sequence counts between two biological replicates
demonstrates high reproducibility (Pearson correlation coefficient ~0.79). c Distribution of sgRNAs targeting positive pathway regulators (CASP8, CASP3,
FADD, BAX, BID, TNFRSF10A, TNFRSF10B) in red, negative regulators (XIAP, BCL2L1) in blue, and random, non-targeting sgRNAs in orange between TRAIL
(y-axis) and PBS (x-axis) treated cell populations. d Scatter plot showing relative enrichment of genes (y-axis) with their corresponding p value (x-axis).
Positive regulators are plotted in red, negative regulators in blue, and random, non-targeting sgRNAs in orange. P values were calculated by Wilcoxon
rank sum test between 30 sgRNAs of one gene and 200 random, non-targeting sgRNAs. Log2 fold change is calculated as median log2 ratio between
normalized sgRNA count of TRAIL- over PBS-treated populations. The vertical line marks a p value of 0.05. e–g Median normalized fold change of all
sgRNAs targeting three essential TRAIL pathway components. A total of 100 sgRNAs are depicted for each gene. Enriched sgRNAs are colored in red,
depleted sgRNAs in grey. The dashed line represents the median fold change of all sgRNAs of the corresponding gene
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(Fig. 2b, c; Additional file 3: Figure S2e, f). Random, non-
targeting sgRNAs showed a median log2 fold change
around 0 (Fig. 2b–d; Additional file 3: Figure S3). The fold
change of every sgRNA targeting CASP8, FADD, and BAX
in the TRAIL treatment versus control group is shown in
Fig. 2e–g. For these genes, more than 80 % of sgRNAs were
enriched after exposure to TRAIL. For other hits, more
than two-thirds of all sgRNAs showed an expected pheno-
type (Additional file 3: Figure S2), indicating that a high
fraction of sgRNAs designed by CLD are indeed functional.
Design parameters for sgRNA library
Selection of sgRNAs with high on-target efficiency can
reduce complexity of pooled libraries and facilitate
screening. Understanding parameters that determine on-
target efficiency is therefore essential for optimal library
design. The results of our screen show that the functional
impact of individual sgRNA is dependent on the exon being
targeted. Using CASP8 as a case example, we demonstrate
that sgRNAs targeting the first exon are less enriched than
those targeting other exons (Fig. 3a, b; p < 0.05, two-sided t-
test). This can be explained by the gene model of CASP8:
while the first exon is used by only few transcript variants,
important functional domains are encoded by several exons
[34]. In addition, nucleotide composition surrounding the
PAM was found to determine on-target activity of sgRNAs
[12, 13, 35]. The net effect of specific nucleotide features is
summarized by two published algorithms [30, 31]. To
assess the predictive power of these algorithms, we deter-
mined the efficiency of individual sgRNAs of FADD, BAX,
and CASP8 by comparing their fold change with the mean
fold change of all sgRNAs of these genes. sgRNAs with a
z-score >1 were classified as functional and those with a
z-score < −1 were considered as non-functional. We then
compared the two groups with regard to the scoring algo-
rithm published by Doench et al. (Doench score) and Xu
et al. (Xu score) by a paired t-test. We show that the
Doench score is significantly different between the groups
(Fig. 3c) whereas no difference was found for the Xu score
(data not shown). Our data confirm that selecting sgRNAs
with high Doench score may increase overall performance
of sgRNA libraries. However, the number of sgRNAs with a
high Doench score is limited (Additional file 3: Figure S4).
In addition to on-target efficiency, the performance of
sgRNA libraries is also determined by the specificity of se-
lected sgRNAs. As shown in Fig. 3d, sgRNAs with no or
few predicted off-targets are rare on a genome scale, as cal-
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Fig. 3 Impact of sgRNA features on library design. a Scatter plot showing log2 fold change of sgRNAs targeting CASP8 relative to their exon
location. The gene models of major transcripts of CASP8 are depicted (ENST00000432109, ENST00000392258, ENST00000323492,
ENST00000264275, ENST00000358485). b Box plots showing fold change of all sgRNAs targeting the first exon of CASP8 compared with other
targeted exons. sgRNAs against the first exon are less enriched (*p≤ 0.05, two-sided t-test). c Comparison of sgRNA features between functional
and non-functional sgRNAs. All sgRNAs of BAX, FADD, and CASP8 were selected for analysis. Fold changes of individual sgRNAs of each gene were
compared with the mean fold change of all sgRNAs of the respective genes. sgRNAs with a z-score >1 were grouped as functional and those with a
z-score <−1 were grouped as non-functional. The on-target score by Doench et al. was calculated for both groups (y-axis) and are presented as box plots.
Differences between groups were determined by a two-sided t-test. d Line graph showing interdependence between number of targetable human
protein coding genes (y-axis), sgRNA coverage per gene (x-axis), and number of off-targets (colored lines). Off-targets are defined as genomic regions with
at least 12 bases of homology to the protospacer of the on-target
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potential off-targets varies considerably between different
organisms (Additional file 3: Figure S5).
Limitations of in silico library design
Taken together, we provide experimental evidence that
the algorithms implemented in CLD can reliably identify
nucleotide sequence with high sgRNA activity. Using
CASP8 as a case example (Fig. 3a, b), we also confirm
previous findings that sgRNAs targeting functional
domains and common exons will more likely result in
loss of function [11]. However, CLD’s ability to select ap-
propriate target sites is dependent on the quality of genome
annotations. While protein-coding transcripts of established
model organisms and the human genome are well anno-
tated, this is not the case for non-coding transcripts or the
coding genomes of many other species, which might lead
to a larger fraction of non-functional sgRNAs. In addition,
off-targets are predicted by CLD based on sequence hom-
ology [27]. This limits off-target detection to sites with
similar sequences (allowing up to three mismatches). Po-
tential off-targets at sites with lower homology could re-
main undetected [36, 37]. Furthermore, the sensitivity for
detecting off-target sites can vary depending on the algo-
rithm used (bowtie versus blast). Thus, the rate of off-
targets might be underestimated by CLD when bowtie is
chosen as the alignment option. We also show that sgRNAs
with high efficiency and/or specificity are rare on the gen-
omic level and unequally distributed among genes, partly
due to differences in gene-model length (Additional file 3:
Figure S1). Furthermore, current knowledge about on-
target efficiency is essentially derived from studies in mur-
ine and human cell lines and it is not known if they apply
to other organisms as well. Therefore, design of compre-
hensive libraries will necessarily include sgRNAs with less
predictable on-target efficiency and multiple off-targets.
Furthermore, additional parameters that are unable to be
computationally predicted can introduce variability in the
performance of CRISPR/Cas9 screens. These include cell
line-specific characteristics such as defective mismatch re-
pair system, mutations/genetic variants [38], and differences
in DNA accessibility to Cas9 [39, 40]. In addition, while
screening for proteins essential for viral or toxin entry
yields only few hits with highly penetrant phenotypes [10],
perturbing complex signaling networks for drug resistance
discovery will most likely reveal less distinct hits. These
drawbacks can be partly overcome by screening with fo-
cused libraries with higher complexity, as was shown for
small hairpin RNA screens [41]. While functional depletion
of protein-coding genes by pooled CRISPR/Cas9 screens is
highly efficient, targeting non-coding genes requires alter-
native strategies and library designs. A potential approach
to dissect the function of enhancers is the use of saturating
mutagenesis, i.e., targeting specific regions with as many
sgRNAs as possible [42, 43].
Conclusions
CLD provides all options to design highly customized
sgRNA libraries to target both protein-coding genes and
non-coding regions. The software is available to the
community as an open source project.
Methods
Software infrastructure
CLD is implemented in Perl and is distributed as a
stand-alone application together with the source code
available at https://github.com/boutroslab/cld. It accepts
46 different input parameters to customize the library de-
sign (Additional file 1: Table S1) and outputs human and
machine-readable files using commonly used sequence
formats (FASTA, GFF; Additional file 4: Table S3). CLD
has been optimized as a command line application for
end-to-end design of sgRNA libraries in a single or paired
design for use with various CRISPR/Cas9 systems. It also
provides a graphical user interface for end-to-end design
of libraries. The program has been combined with all its
source packages and dependencies using the Perl-
archiver (PAR) package. CLD was built and tested using
the software versions as listed in Additional file 10:
Table S9. CLD requires bowtie2 [28], bowtie [27], and
blastn [29] for short-read mapping to be installed. CLD
and the pre-built libraries can be downloaded from
http://www.dkfz.de/signaling/crispr-downloads/. CLD is
distributed as Unix binary bundle (https://github.com/
boutroslab/cld).
Scoring of sgRNAs
Target sites are identified by scanning each gene for the
presence of specific PAMs. CLD creates a nucleotide
index of each position containing a PAM. sgRNAs that
harbor a TTTTT motif are excluded from further analysis
as they would hinder RNA transcription [44]. When a
match is found, three scores are calculated to evaluate the
target site: annotation, specificity, and on-target efficiency
score. The annotation score evaluates the efficiency of
sgRNAs within the context of a gene model. Annotations
such as exons, coding regions, or genes targeted by each
sgRNA are found by searching all annotations at the target
coordinates in an interval tree. This binary tree contains
the coordinates and details of all annotations for the gen-
ome. The rooted binary tree structure can be searched effi-
ciently (O = log(n)), minimizing computational resources.
Trees are built and stored for every chromosome individu-
ally and are then retrieved from pre-computed binary files.
The annotation score relies on general assumptions about
positions at which sgRNAs should bind to efficiently alter
the function of the respective gene. These positions are
generally found in common transcripts and in coding
exons, preferentially within close proximity of the transcrip-
tion start site. The annotation score is calculated as follows:
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first it is set to 0; then all annotations overlapping the re-
gion at which the sgRNA under investigation binds are
parsed; for each coding sequence and exon match, 5, di-
vided by the number of the respective exons, is added; for
every transcript it hits, 1 is added; for every start or stop
codon hit, 1 is added; for every predicted CpG island, 1 is
subtracted from the score. In summary, the annotation
score enables CLD to sort sgRNA designs according to
preferable target regions within a gene model. The specifi-
city score is based on the assumption that specificity is de-
termined by sequence homology of the 20 nucleotides
preceding the PAM. Assuming that the first 5′ bases of the
protospacer can possess ambivalent specificity [45], the user
can exclude them from the specificity calculations. The
remaining protospacer is mapped against the target genome
using bowtie or blast in different adjustable modes (high or
low sensitivity). For the highest sensitivity, up to three mis-
matches in the protospacer are allowed in the mapping.
Furthermore, each mapped protospacer is required to be
followed by a specific PAM. When all on- and off-targets of
a single sgRNA are mapped, the specificity score is calcu-
lated. The score starts with a maximum of 100. If no off-
targets exist, the score remains at 100. For each off-target,
the number of homologous nucleotides of the off-target is
subtracted from the score. This way, 20 is subtracted for a
perfectly matching first off-target and another 10 is sub-
tracted for a perfectly matching second off-target. For
sgRNA libraries, all identified designs are sorted by best
suitable annotation first, followed by target specificity and
efficacy. sgRNA designs with the highest overall score are
selected for inclusion in the library (see Additional file 11:
Table S12 for details). On-target efficiency, determined by
the nucleotide composition surrounding the NGG/NAG
PAM site, is assessed by two published scoring algorithms:
the Doench score [30] and the Xu score [31]. Optionally,
an additional, user-provided score can be used to assess on-
target activity. The custom score is only applied if provided
to CLD as an external function. The custom score is limited
to the assessment of a 30mer base sequence, starting at 24
nucleotides upstream of the PAM. The range of the score is
limited to 0 to 1. The user may choose to further sort all
sgRNA by an on-target score.
Library design
We used CLD to design a custom sgRNA library consist-
ing of 12,471 sgRNAs, of which 12,271 were directed
against a total of 408 genes and 200 were random, non-
targeting sgRNAs serving as controls. A list of selected
genes can be found in Additional file 2: Table S2. All
genes were covered with 30 sgRNAs per gene with the
exception of CASP8, FADD, and BAX, which were cov-
ered with 100 sgRNAs. The library was designed by
using the “end-to-end” functionality of CLD. Input files
were the gene list from Additional file 2: Table S2 and
the list of parameters in Additional file 12: Table S10.
The parameters were set to score designs best if they
target protein-coding regions of common exons outside
of CpG islands. The source of all gene sequences and
the basis of the off-target analysis was the human gen-
ome build GRCh37 ENSEMBL release 75. Targets were
restricted to 23 nucleotides including PAM. The PAM
was restricted to NGG and only ten off-targets were
allowed, each with up to three possible mismatches in
the first 16 5′ nucleotides. Off-targets were checked for
each individual sgRNA by mapping the target site back
to the genome. Before mapping, each sgRNA was
trimmed for its last four nucleotides and mapped to the
genome together with any possible PAM (AGG, TGG,
CGG, GGG, AAG, TAG, CAG, GAG, etc.). Mismatches
in the PAM were not allowed. A custom Perl script was
used to generate random non-targeting sgRNA designs
(Additional file 13: Supplementary file 1). These sgRNAs
were designed by randomly generating 20,000 × 20mer
oligonucleotides, which are mapped back to the human
genome with loose parameters (ignore first four 5′-nu-
cleotides, allow three further mismatches). Designs with
successful alignment were excluded from this list. This
resulted in a list of 2000 sgRNAs which did not map to
the human genome, were compliant with the cloning
strategy (no BbsI restriction sites), and were able to be
expressed by DNA-dependent RNA polymerases (no
TTTTT or GGGGG motifs). For library construction,
each target site was trimmed by its first 5′ nucleotide
and replaced by guanine. Adapters for cloning were
added (Additional file 14: Table S11) and sequences with
hindering restriction sites (GAAGAC, GTCTTC,
GAATTC, CTTAAG, CAATTG, GTTAAC, CTCGAG,
GAGCTC) were removed. Finally, designs were sorted
hierarchically, in the following order: gene annotation,
specificity, efficacy score. The 30 highest ranked designs
were chosen for each gene. For CASP8, FADD, and
BAX, designs from previously published libraries [12, 13]
were included in addition to those designed by CLD. As
a result, a set of uniquely named files is created in the
output directory. A detailed description of each file can
be found in Additional file 4: Table S3.
Plasmid vectors
To clone Marie-U6-onchip, we modified the lentiviral vec-
tor pLKO.1 [46]. We first digested pLKO.1 with MefI
(NEB) and then introduced gBlocks (Integrated DNA
Technologies) encoding a FRT1-CMV-rtTA3-WPRE cas-
sette using sequence- and ligation-independent multi-
fragment cloning (InFusion cloning, Clontech). Then, the
modified pLKO.1 was cut with AleI and KpnI, which re-
moved the PGK-puromycin resistance cassette. Next, the
U6 promotor and a truncated sgRNA cassette together
with a mPGK-EM7-promotor-driven blasticidin-resistance
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cassette as well as a FRT3 site were introduced using se-
quence- and ligation-independent multi-fragment cloning
(InFusion cloning, Clontech) of gBlocks (Integrated DNA
Technologies). The blasticidin sequence and pLKO.1 were
modified to remove all BbsI sites. Placing the blasticidin
expression cassette under the control of an Escherichia
coli promoter next to the sgRNA cassette allowed anti-
biotic selection of bacterial colonies containing correctly
assembled vectors. The sgRNA cassette of Marie-U6-
onchip vector contains only half of the sgRNA scaffold,
preceded by two BbsI sites (referred to as on-chip design).
The oligo library encodes the other half of the sgRNA cas-
sette. Final lentiviral vectors were assembled by ligation of
pooled oligos.
Construction of sgRNA libraries
Oligonucleotide pools consisting of 12,471 different 99mers
were ordered from CustomArrays Inc. (Bothell, WA, USA).
The oligo sequences are provided in Additional file 14:
Table S11 and Additional file 15: Supplementary file 2. We
PCR amplified 1 ng of this oligo pool using primers
onchip-F and onchip-R, Q5 Hot Start HF Polymerase
(NEB) and the following PCR conditions: 98 °C for 10 s,
16 cycles of 98 °C for 10 s, 64 °C for 15 s, and 72 °C for
15 s, with a final extension at 72 °C for 2 min. The products
of five PCR reactions were pooled and column purified with
a NucleoSpin Gel and PCR clean-up kit (Machery-Nagel),
followed by restriction digestion with Fast Digest BbsI
(Thermo Fisher) for at least 12 h at 37 °C and another
round of column purification. After every purification step,
correct oligo size was confirmed using DNA High Sensitiv-
ity Assay on a BioAnalyzer 2100 (Agilent). The backbone
vector Marie-U6-onchip was digested with Fast Digest BbsI
and dephoshorylated with Fast Alkaline Phosphatase (NEB)
for 16 h and loaded on a 0.8 % agarose gel to confirm suc-
cessful digestion. The vector was then excised from the gel
and purified using a NucleoSpin Gel and PCR clean-up kit
(Machery-Nagel). Concentrations of digested backbone
vector and oligo pools were determined using a Qubit
dsDNA HS Assay (Life Technologies). We ligated 10 ng of
backbone vector and 340 ng of oligonucleotides per reac-
tion using T4 DNA Ligase (NEB) for 16 h at 16 °C. Five
reactions were combined and cleaned using a Qiaquick
PCR purification Kit (Qiagen) and eluted into nuclease-free
water. The concentration of ligated vector was determined
by Qubit dsDNA HS Assay (Life Technologies). A total of
ten electroporations were performed according to the man-
ufacturer’s protocol using 1 ng of ligated vector and 25 ul
of DH10beta E. coli Electrocompetent Cells (NEB). Each
electroporation reaction was then plated onto two 15-cm
diameter agar plates containing Luria broth medium (Life
Technologies) and 100 μg/ml carbenicillin. After overnight
incubation at 37 °C, bacterial colonies equaling 500-fold
library complexity were scraped off all plates, pooled, and
purified with a Plasmid Maxi Kit (Qiagen).
Cell culture and generation of Cas9-expressing cells
The colorectal cancer cell line SW480 is highly sensitive
to TRAIL (Additional file 3: Figure S8) and was previously
used to study TRAIL signaling [32, 47]. SW480 cells were
maintained in RPMI medium (Invitrogen) containing
10 % fetal calf serum (Biochrom). HEK 293T cells were
kept in high glucose Dulbecco's modified Eagle's medium
(DMEM) (Invitrogen) supplemented with 10 % fetal calf
serum (Biochrom). Both cell lines were obtained from
ATCC. Authentication of genotype by SNP profiling (Mul-
tiplexion) was performed on all cell lines and regular tests
confirmed the absence of mycoplasma infection. Stable
Cas9-GFP expression was achieved by using piggybac
transposase/transposon technology and subsequent selec-
tion of green fluorescent protein (GFP)-positive cells by
fluorescence-activated cell sorting (FACS) (T.Z., M.Br.
unpublished).
Lentivirus production and infection
For lentivirus production, HEK293T cells were seeded into
two T225 flasks (Nunc) at a density of 6 × 105 cells/ml
(30 ml per flask) and incubated for 24 h, after which a
confluence of 80 % is reached. We added 90 μg of sgRNA
library, 60 μg psPAX2, and 20 μg of pMDM2 (both from
Addgene) to a total of 6 ml RPMI and 300 μl of TransIT
(Mirus) was added to 5.7 ml of RMPI. After 10 min, both
solutions were mixed and incubated for another 30 min
before adding to both flasks (6 ml/flask). After 24 h,
medium was exchanged to DMEM containing 10 % fetal
calf serum and 1 U/ml DNAseI (Thermo Fisher). Viral
supernatant was harvested 48 h after transfection and
stored at −80 °C until use. For determining multiplicity of
infection (MOI), lentiviral supernatant was generated
using the GFP-expressing vector pLKO-G3 (Addgene)
under the same conditions and used as a surrogate.
Generation of mutant cell libraries and screening
To determine the MOI, 105 SW480 cells were seeded into
each well of a 12-well plate (Greiner). While in suspen-
sion, cells were infected with increasing volumes of the
pLKO-G3 derived lentivirus in the presence of 5 μg/ml
polybrene (Merck Millipore). Cells were detached 72 h
post-infection and resuspended in MACS buffer (PBS with
1 % fetal calf serum and 2 μM EDTA). The percentage of
GFP positive cells for each volume of lentiviral super-
natant was determined by FACS analysis on a FACS Canto
(BD). For generation of mutant libraries, 4 × 107 SW480
cells were infected with the sgRNA lentiviral library
equivalent to an MOI of 0.2–0.3 (1000-fold library com-
plexity) in the presence of 5 μg/ml polybrene (Merck
Millipore). After 72 h, cells were detached and reseeded
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onto new flasks in the presence of 4 μg/ml blasticidin (Life
Technologies). Antibiotic selection was terminated after
72 h and cells were allowed to recover for another 5 days.
Cells were then harvested and either stored in liquid ni-
trogen or directly used for screening. For screening, 1.4 ×
107 cells were used per replicate, equivalent to a >1000-
fold library complexity. For each condition, two replicates
were used. After 24 h, cells were treated with 100 ng/ml
of water-soluble SuperKillerTRAIL (Enzo Life Sciences)
or PBS for 24 h. The medium was then replaced and the
cells were allowed to recover for 5 days. Thereafter, Super-
KillerTRAIL was added for another 24 h, followed by
medium change and a recovery phase of 5 days. After a
total of 12 days, at least 1.4 × 107 cells were harvested
from each replicate.
Genomic DNA isolation and library preparation for
Illumina sequencing
Genomic DNA from cell pellets containing 1.4 × 107 cells
were extracted using the DNAeasy Blood and Tissue Kit
(Qiagen) according to the manufacturer’s protocol. For
amplification of the sgRNA-containing regions, a total of
25 PCR reactions were performed using 1 μg genomic
DNA per reaction as input, Q5 Hot Start HF polymerase
(NEB), and primers SEQ-F1 and SEQ-R1 with the follow-
ing conditions: 98 °C for 2 min, 25 cycles of 98 °C for 10 s,
62 °C for 15 s, and 72 °C for 30 s, with a final extension at
72 °C for 2 min. The PCR product was cleaned using a
QIAquick PCR purification Kit and eluted into nuclease-
free water. The DNA concentration of the eluate was de-
termined using Qubit HS DNA Assay. The purified PCR
product (5 ng) was used for enrichment PCR with Q5 Hot
Start HF polymerase (NEB), primers SEQ-F2 and SEQ-R2,
and the following PCR conditions: 98 °C for 2 min, 15 -
cycles of 98 °C for 10 s, 72 °C for 15 s, and 72 °C for 30 s,
with a final extension at 72 °C for 2 min. The PCR product
was purified with Agencourt AMPure XP beads at a
product-to-beads ratio of 1:1.2. The purified libraries were
controlled for correct size using DNA High Sensitivity
Assay on a BioAnalyzer 2100 (Agilent) and then se-
quenced on a MiSeq (Illumina) by 100-bp single-end se-
quencing and addition of 20 % PhiX Control v3 (Illumina)
at a concentration of 8 pM. Two MiSeq runs were per-
formed each containing one replicate of the TRAIL- and
PBS-treated conditions.
Illumina sequencing of plasmid libraries
For determining library coverage, 750 ng of the puri-
fied plasmid library was amplified using primers SEQ-
F2 and SEQ-R2, Phusion High Fidelity Polymerase
(Biozym), and the following PCR conditions: 98 °C for
2 min, 15 cycles of 98 °C for 10 s, 72 °C for 15 s, and
72 °C for 30 s, with a final extension at 72 °C for 2 min.
The PCR product was purified with a Qiaquick PCR
purification kit (Qiagen). The purified libraries were
controlled for correct size using DNA High Sensitivity
Assay on a BioAnalyzer 2100 (Agilent) and then se-
quenced on a HiSeq 2500 (Illumina) by 100-bp paired-
end sequencing and addition of 20 % PhiX Control v3
(Illumina) at a concentration of 8 pM. All primer se-
quences can be found in Additional file 14: Table S11.
Data processing and analysis
Reads reported by the MiSeq analysis were quality
checked using FASTQC and analyzed FASTQ data using
a custom Perl script, which can be found in Additional
file 16: Supplementary file 3. The sequencing reads were
checked and trimmed for the adapters, which were added
in silico before on-chip synthesis of the library. These
adapters are part of the expression cassette resulting in the
following required pattern: ACCG(.{20})T{2,4}AGAGC
(Perl-regular expression). The target site (all nucleotides in
the parentheses of the pattern) is saved in a new variable
and in the next step mapped back to the original library. As
a result we obtained sgRNA count tables for each sample:
negative control 1 (PBS1), negative control 2 (PBS2),
TRAIL treatment 1 (TRAIL1), and TRAIL treatment 2
(TRAIL2) (Additional file 5: Table S4, Additional file 6:
Table S5, Additional file 7: Table S6, Additional file 8: Table
S7, respectively). The raw read counts were processed using
an algorithm implemented in R. The source code is at-
tached in Additional file 17: Supplementary file 4. In short,
raw counts were collected and divided by the respective
sample median for normalization and the log2 fold change
was calculated as the log2-ratio between the mean read
count in treated samples and the mean read count per
sgRNA of the control samples (Fig. 2e–g; Additional file 3:
Figure S2,S3). Read counts in Fig. 2b, c were normalized.
The median fold change of the random controls was set to
zero by subtracting it from every fold change in the dataset.
This corrected for the general loss of coverage dur-
ing the TRAIL treatment. For testing sample sgRNAs
against random controls, a Wilcoxon rank sum test
was performed under the null hypothesis that the
true shift of means is larger than zero. The statistical
significance of differences in parameters between
enriched and non-enriched sgRNAs in sample genes
was assessed using a two-sided Student’s t-test as
implemented in R with default parameters under the
null hypothesis that the true difference in means is
larger than zero. All analysis scripts can be found in
Additional file 17: Supplementary file S4.
Availability of data and material
Raw sequencing reads have been deposited at the Sequence
Read Archive (SRA; project ID SRP070542): PBS-treated
pool 1, SRR3178382; PBS-treated pool 2, SRR3178383;
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TRAIL-treated pool 1, SRR3178384; TRAIL-treated pool 2,
SRR3178385.
A release version of CLD can be found at http://
dx.doi.org/10.5281/zenodo.46772. The software presented
here is licenced under GPLv2. All other scripts and soft-
ware to reproduce the results can be found in the supple-
mental material.
Ethics approval
No ethics approval was required for this study.
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